NCT03861715

Single Follicular Dexarelix for LH Suppression During Ovarian Stimulation in Oocyte Donors.

Single Follicular Dexarelix, a New Long Acting GnRH- Antagonist for LH Suppression During Ovarian Stimulation in Oocyte Donors. A Randomised Control Trial.

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 180 (estimated)
• Sponsor: Assisting Nature · Academic / Other
• Sex: Female
• Age: 20 Years – 34 Years
• Healthy volunteers: Accepted

Summary

A randomized prospective study in the evaluation of the long acting GnRH antagonist Degarelix against the classical multidose regime with Ganirelix for LH suppression during the follicular phase of an ovarian stimulation cycle in oocyte donors.

Detailed description

A randomized prospective study of the use of single dose of the long acting GnRH antagonist Degarelix for ovarian stimulation cycle in oocyte donors: Ovarian stimulation started on cycle Day2 with gonadotropins 175-300 IU and either GnRH antagonist single dose Degarelix or multidose GnRH antagonist Ganirelix initiated on Day6 of the stimulation cycle. Agonist triggering was used in both groups for oocyte maturation. Blastocyst formation rate and Live Birth Rates were estimated for both groups.

Conditions

• Infertility
• Premature Ovarian Failure

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	live birth rate	The blastulation rate and live birth rate according to the protocol of COS

Timeline

• Start date: 2017-01-01
• Primary completion: 2021-12-01
• Completion: 2021-12-01
• First posted: 2019-03-04
• Last updated: 2020-10-08

Locations

1 site across 1 country: Greece